Pain Therapeutics (PTIE) 2.73 $PTIE Global Pain

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Pain Therapeutics (PTIE) 2.73 $PTIE

Global Pain Therapeutics Report 2016 - Focus on Latest Drugs, Markets and Companies - Research and Markets
PR Newswire Europe - Fri May 27, 7:10AM CDT
Research and Markets has announced the addition of Jain PharmaBiotech's new report "Pain Therapeutics - Drugs, Markets and Companies" [http://www.researchandmarkets.com/research/thf6d3/pain_therapeutics] to their offering.
PTIE: 2.73 (+0.03)

Global Pain Therapeutics Report 2016-2025 - Drugs, Markets and Companies Forecasts
GlobeNewswire - Fri May 27, 3:17AM CDT
Research and Markets has announced the addition of Jain PharmaBiotech's new report "Pain Therapeutics - Drugs, Markets and Companies" to their offering.
PTIE: 2.73 (+0.03)

Global Peripheral Neuropathic Pain Therapeutics Pipeline Report 2016 - 10 Companies & Drug Profiles - Research and Markets
BusinessWire - Thu May 26, 8:36AM CDT
Research and Markets has announced the addition of the "Peripheral Neuropathic Pain - Pipeline Review, H1 2016" report to their offering.
PTIE: 2.73 (+0.03)

DURECT Announces FDA Advisory Committee Meeting for REMOXY®
PR Newswire - Thu May 19, 8:05AM CDT
DURECT Corporation (Nasdaq: DRRX) today announced that its licensee, Pain Therapeutics (Nasdaq: PTIE) has announced that an Advisory Committee of the U.S. Food and Drug Administration (FDA) will review the REMOXY® New Drug Application (NDA), in a joint meeting of the FDA's Anesthetic and Analgesic Drug Products Advisory Committee and Drug Safety and Risk Management Advisory Committee tentatively scheduled for August 5, 2016. Pain Therapeutics also stated that the FDA advised them that the Prescription Drug User Fee Act (PDUFA) date for the REMOXY NDA of September 25, 2016 is unchanged.
DRRX: 1.95 (+0.01), PTIE: 2.73 (+0.03)

Pain Therapeutics Announces FDA Advisory Committee Meeting for REMOXY(R)
GlobeNewswire - Thu May 19, 8:00AM CDT
- August 5 is FDA's Tentative Date for Advisory Committee Meeting -
PTIE: 2.73 (+0.03)

Pain Therapeutics to Present New REMOXY Data At American Pain Society Meeting
GlobeNewswire - Wed May 11, 8:05AM CDT
Pain Therapeutics, Inc. (Nasdaq TIE) today announced that researchers will present new data around REMOXY's abuse-deterrent properties at the 35 Annual Scientific Meeting of the American Pain Society (APS), held this year in Austin, TX.
PTIE: 2.73 (+0.03)

DURECT Announces New REMOXY® Data being Presented at American Pain Society Meeting
PR Newswire - Wed May 11, 8:05AM CDT
DURECT Corporation (Nasdaq: DRRX) today announced researchers will present new data around REMOXY's abuse-deterrent properties at the 35th Annual Scientific Meeting of the American Pain Society (APS) meeting. The scientific poster is titled "REMOXY: Human Abuse Potential Study of an Extended-Release Oxycodone Formulation." Co-authors Lynn Webster and Nadav Friedmann are scheduled to present the data at APS on Thursday, May 12, 2016, from 3:45 to 5:15 pm Central Time. This scientific poster will be available for review by the general public on DURECT's website at www.durect.com.
DRRX: 1.95 (+0.01), PTIE: 2.73 (+0.03)

Pain Therapeutics Reports Q1 2016 Financial Results
GlobeNewswire - Thu May 05, 3:05PM CDT
Pain Therapeutics, Inc. (Nasdaq TIE) today reported financial results for the first quarter of 2016. Net loss in Q1 2016 was $5.8 million, or $0.13 per share, compared to a net loss in Q1 2015 of $2.6 million, or $0.06 per share.
PTIE: 2.73 (+0.03)

Global Visceral Pain Therapeutics Pipeline Report 2016 - Research and Markets
BusinessWire - Thu Apr 28, 1:06PM CDT
Research and Markets has announced the addition of the "Visceral Pain - Pipeline Review, H1 2016" report to their offering.
PTIE: 2.73 (+0.03)

FDA Accepts REMOXY NDA for Review, Sets PDUFA Date of September 25, 2016
GlobeNewswire - Tue Apr 12, 3:05PM CDT
- Company Will Host Conference Call on Wednesday, April 13, 8:30am EDT -
PTIE: 2.73 (+0.03)

Diabetic Neuropathic Pain Therapeutics Pipeline Review H1 2016 - Research and Markets
BusinessWire - Wed Mar 30, 1:54PM CDT
Research and Markets has announced the addition of the "Diabetic Neuropathic Pain - Pipeline Review, H1 2016" report to their offering.
PTIE: 2.73 (+0.03)

Centrexion Therapeutics Expands Pain Pipeline with Acquisition of Three New Analgesic Candidates from Boehringer Ingelheim
BusinessWire - Wed Mar 30, 6:00AM CDT
--Acquisition Creates One of the Largest Exclusively Pain-Focused, Non-Opioid Pipelines in Active Development
PTIE: 2.73 (+0.03)

DURECT Announces Resubmission of REMOXY® New Drug Application to the U.S. Food and Drug Administration
PR Newswire - Tue Mar 29, 10:15AM CDT
DURECT Corporation (Nasdaq: DRRX) today announced its licensee, Pain Therapeutics (Nasdaq: PTIE), has resubmitted the New Drug Application (NDA) for REMOXY® (oxycodone capsules CII) to the U.S. Food and Drug Administration (FDA). Pain Therapeutics has stated that they expect to be notified by the FDA of a Prescription Drug User Fee Act (PDUFA) action date within 30 days. The original REMOXY NDA has a Priority Review Designation.
DRRX: 1.95 (+0.01), PTIE: 2.73 (+0.03)

Pain Therapeutics Resubmits REMOXY New Drug Application to the U.S. Food and Drug Administration
GlobeNewswire - Tue Mar 29, 7:00AM CDT
Pain Therapeutics, Inc. (Nasdaq TIE) announced today that it has resubmitted to the U.S. Food and Drug Administration (FDA) a New Drug Application (NDA) for REMOXY(R), an abuse-deterrent formulation of extended-release oxycodone (CII) capsules. Pain Therapeutics expects to be notified by the FDA of a Prescription Drug User Fee Act (PDUFA) action date within 30 days. The original REMOXY NDA has a Priority Review designation.
PTIE: 2.73 (+0.03)

Global Pain Therapeutics, Inc. Market Overview Report Product Pipeline Review 2015 - Acute Market Reports
M2 - Fri Feb 05, 5:39AM CST
'PAIN THERAPEUTICS, INC. - Product Pipeline Review - 2015', provides an overview of the PAIN THERAPEUTICS, INC.'s pharmaceutical research and development focus.
PTIE: 2.73 (+0.03)

Cancer Pain Pipeline Review, H2 2015
M2 - Fri Feb 05, 4:26AM CST
Research and Markets (http://www.researchandmarkets.com/research/3tjd78/cancer_pain) has announced the addition of the "Cancer Pain - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Cancer Pain, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cancer Pain and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Cancer Pain Overview - Therapeutics Development - Pipeline Products for Cancer Pain - Overview - Pipeline Products for Cancer Pain - Comparative Analysis - Cancer Pain - Therapeutics under Development by Companies - Cancer Pain - Therapeutics under Investigation by Universities/Institutes - Cancer Pain - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Cancer Pain - Products under Development by Companies - Cancer Pain - Products under Investigation by Universities/Institutes - Cancer Pain - Companies Involved in Therapeutics Development - Amgen Inc. - Amorsa Therapeutics Inc. - AngioChem Inc. - Aphios Corporation - AstraZeneca Plc - BCN Peptides, S.A. - Benitec Biopharma Limited - BioDelivery Sciences International, Inc. - ChironWells GmbH - Daiichi Sankyo Company, Limited - Fujimoto Pharmaceutical Corporation - Grunenthal GmbH - GW Pharmaceuticals Plc - Hisamitsu Pharmaceutical Co., Inc. - Immupharma Plc - IntelGenx Corp. - Kolon Life Science, Inc. - Nektar Therapeutics - Neurocentrx Pharma Ltd. - Orion Oyj - Pain Therapeutics, Inc. - Pfizer Inc. - Pharmaleads - PsychoGenics, Inc. - Recordati S.p.A. - Ribomic Inc. - Virobay Inc. - WEX Pharmaceuticals Inc. - Winston Pharmaceuticals, Inc. - Zynerba Pharmaceuticals, Inc. For more information visit http://www.researchandmarkets.com/research/3t...ancer_pain
BDSI: 2.48 (-0.07), PFE: 37.25 (+0.36), AMGN: 174.20 (+2.17), ZYNE: 9.33 (+0.49), NKTR: 17.75 (+0.46), AZN: 33.92 (-0.22), VBAY: (), PTIE: 2.73 (+0.03)

Chronic Pain Therapeutics Pipeline Review, H2 2015
M2 - Wed Feb 03, 10:38AM CST
Research and Markets (http://www.researchandmarkets.com/research/vxjcvw/chronic_pain) has announced the addition of the "Chronic Pain - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Chronic Pain, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chronic Pain and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Chronic Pain Overview - Therapeutics Development - Pipeline Products for Chronic Pain - Overview - Pipeline Products for Chronic Pain - Comparative Analysis - Chronic Pain - Therapeutics under Development by Companies - Chronic Pain - Therapeutics under Investigation by Universities/Institutes - Chronic Pain - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Chronic Pain - Products under Development by Companies - Chronic Pain - Products under Investigation by Universities/Institutes - Chronic Pain - Companies Involved in Therapeutics Development Companies Featured (Partial List) - AbbVie Inc. - Acadia Pharmaceuticals Inc. - Adynxx, Inc. - Allergan Plc - Amorsa Therapeutics Inc. - arGEN-X BV - AskAt Inc. - Astellas Pharma Inc. - Astraea Therapeutics, LLC - AstraZeneca Plc - BioDelivery Sciences International, Inc. - Bionomics Limited - Cara Therapeutics, Inc. - Charleston Laboratories, Inc. - ChironWells GmbH - Collegium Pharmaceutical, Inc. - CoLucid Pharmaceuticals, Inc. - Convergence Pharmaceuticals Ltd. - Creabilis SA - Crinetics Pharmaceuticals, Inc. - Cyclenium Pharma, Inc. - Cytogel Pharma, LLC - Daewoong Pharmaceutical Co., Ltd. - Daiichi Sankyo Company, Limited - Dompe Farmaceutici S.p.A. - Echo Pharmaceuticals B.V. - Egalet Corporation - Eli Lilly and Company - Elite Pharmaceuticals, Inc. - Glenmark Pharmaceuticals Ltd. - Grunenthal GmbH - Heron Therapeutics, Inc. - INSYS Therapeutics, Inc. - Johnson & Johnson - Kareus Therapeutics, SA For more information visit http://www.researchandmarkets.com/research/vx...ronic_pain
BDSI: 2.48 (-0.07), COLL: 12.12 (-0.01), LLY: 83.46 (+0.57), AGN: 254.79 (+1.84), JNJ: 125.36 (+0.13), INSY: 15.95 (+0.30), EGLT: 7.31 (-0.08), ACAD: 37.38 (+0.34), CLCD: 8.70 (unch), HRTX: 18.78 (+2.16), AZN: 33.92 (-0.22), ABBV: 66.67 (+0.44), PTIE: 2.73 (+0.03)

Global Moderate Pain Development Pipeline Insights Report 2016
M2 - Mon Feb 01, 5:54AM CST
Research and Markets (http://www.researchandmarkets.com/research/zcjhtj/moderate) has announced the addition of the "Moderate Pain-Pipeline Insights, 2016" report to their offering. Moderate Pain-Pipeline Insights, 2016 provides in depth insights on the pipeline drugs and their development activities around the Moderate Pain. The report covers the product profiles in various stages of development including Discovery, Pre-clinical, IND, Phase I, Phase II, Phase III and Preregistration. Report covers the product clinical trials information and other development activities including technology, licensing, collaborations, acquisitions, fundings, patent and USFDA & EMA designations details. The report also provides detailed information on the discontinued and dormant drugs that have gone inactive over the years for Moderate Pain. The report also assesses the Moderate Pain therapeutics by Monotherapy, Combination products, molecule type and Route of Administration. Scope - The report provides competitive pipeline landscape of Moderate Pain - The report provides pipeline products under drug profile section which includes product description, MOA, licensors & collaborators, development partner and chemical information - Coverage of the Moderate Pain pipeline on the basis of target, MOA, route of administration, technology involved and molecule type - The report reviews key players involved in the therapeutics development for Moderate Pain and also provide company profiling - The report also gives the information of dormant and discontinued pipeline projects - Pipeline products coverage based on various stages of development ranging from preregistration till discovery and undisclosed stages - Provides pipeline assessment by monotherapy and combination therapy products, stage of development and molecule type Key Topics Covered: - Moderate Pain Overview - Moderate Pain Pipeline Therapeutics - Moderate Pain Therapeutics under Development by Companies - Moderate Pain Filed and Phase III Products - Comparative Analysis - Moderate Pain Phase II Products - Moderate Pain Phase I and IND Filed Products - Moderate Pain Discovery and Pre-Clinical Stage Products - Moderate Pain - Therapeutics Assessment - Assessment by Monotherapy Products - Assessment by Combination Products - Assessment by Route of Administration - Assessment by Molecule Type - Moderate Pain - Discontinued Products - Moderate Pain - Dormant Products - Companies Involved in Therapeutics Development for Moderate Pain For more information visit http://www.researchandmarkets.com/research/zcjhtj/moderate
PTIE: 2.73 (+0.03)

Global Cancer Pain Therapeutics Market 2015-2019 - Key Vendors are BioDelivery Sciences, ProStrakan Group, Teva Pharmaceuticals & Yamaha - Research and Markets
BusinessWire - Fri Jan 29, 7:31AM CST
Research and Markets (http://www.researchandmarkets.com/research/36pfgs/global_cancer) has announced the addition of the "Global Cancer Pain Therapeutics Market 2015-2019" report to their offering.
PTIE: 2.73 (+0.03)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Tenax Therapeutics Facing Class Action: DEC 28 Deadline

Updated Category News Views 65

Legal Storm Over Tenax Therapeutics Just what the doctor didn't order—legal headaches for Tenax Therapeutics, Inc. (NASDAQ:TENX). Yup, folks, buckle up because we're diving into another class action mudslinging match that’s setting the markets wagging. Berger Montague's law trebuchet is aimed squarely at Tenax and every investor should know the target’s outline....

Continue Reading
NestWorks' C500: Shaking Up CNC at Formnext 2026

Updated Category News Views 108

NestWorks C500: A Game Changer for Makers Folks, gather 'round, because NestWorks is turning heads with their C500 desktop CNC machine. As it lands firmly on TIME’s Best Inventions of 2026 list, this ain't just another gadget adorning a workshop—all eyes are on it at Formnext 2026. From November 17–20, Frankfurt is the stage where NestWorks plans to showcase how...

Continue Reading
Guangdong-US Trade: LED Screens, Beef & Trust Make Waves

Updated Category News Views 29

Guangdong's Economic Ballet with the U.S. Grab a cup of coffee, and let's unravel how Guangdong and the U.S. are tangoing their way through trade like nobody's business! Guangdong, the heavyweight champ for U.S.-China trade transactions, notched up a cool 685.27 billion yuan ($102 billion) in the first eight months of 2026. That's a healthy jump of 6.9% year on year, mind...

Continue Reading
Sasol AGM Resolutions Passed in One Swift Swing

Updated Category News Views 65

Sasol's AGM Delivers Smooth Sailing for Shareholders Can't say I'm surprised, but Sasol's annual general meeting on the 13th of November went off without a hitch—unless, of course, you're one of those folks who just loves fireworks at these gatherings. The entire set of resolutions danced through with a resounding "Aye," making it one heck of a day for anyone banking on...

Continue Reading
Ballard's Q3 2026: Navigating Losses and Bold Moves

Updated Category News Views 53

Ballard’s Financial Puzzles in Q3 2026 Riding the rough waters of the third quarter in 2026, Ballard Power Systems set out its stall with some eyebrow-raising numbers. This ain't the bustling diner vibe we normally see for a thriving business. The results paint a cautious picture sprinkled with strategic shifts that demand a keen eye. GeoPura Acquisition: A Strategic...

Continue Reading
LONGi's Four Paths to Global Green Development

Updated Category News Views 164

LONGi's Vision: A Cleaner, Greener Future Amidst the buzz at COP31 in Antalya, LONGi is making waves with promises of a cleaner future. They're not just throwing around eco-friendly slogans—this company's laying down real pathways to tackle climate change, one solar panel at a time. Aiming for Industrial Transformation LONGi's got their sights set on shaking up...

Continue Reading
MacKenzie-Childs Grinds Into Spotlight with Oprah's Nod

Updated Category News Views 40

Oprah's Golden Touch: 30 Years Strong Every year, there are a few select spots that brands covet like a hawk on a rabbit hunt. Getting on Oprah’s 'Favorite Things' list is surely one of them. Just like that, the MacKenzie-Childs Electric Salt and Pepper Grinder Set has muscled its way into the 2026 selection. Spare me the bells and whistles; this is like hitting the...

Continue Reading
CureGene's CG-0416: Promising Weight Loss Breakthrough

Updated Category News Views 125

Game-Changer in Weight Management? Oh, the obesity world is buzzing, folks! There's some big noise coming from CureGene, and it's catching the attention of every lab-coat smarty in town. They just tossed out some preclinical data on CG-0416 at Obesity Week 2026 that could shake up how we tackle weight loss. Anyone still clinging to their old diet books might want to take...

Continue Reading
Stark Future Amasses €150M, Revving Up Electric Bike Dominance

Updated Category News Views 115

Well, if you've been keeping your eye on electric vehicles, this is a story that might raise those eyebrows. Stark Future, a name perhaps not buzzing on every street just yet, has gone and done it—snagged over €150 million in fresh capital. Breaking Barriers with Record-breaking Numbers Stark Future didn't just make a ripple; they caused a tsunami. This buzzing...

Continue Reading
Jones Soda Expands into Nutrition with UCAN Deal

Updated Category News Views 59

Well, Jones Soda Co. (CSE: JSDA) is stirring the pot with its recent move to acquire the UCAN functional nutrition assets. Popped the news on November 12, 2026, and it turns out they've shelled out a cool $700,000 in cash and taken on $500,000 in liabilities for the privilege. This isn't some casual shuffle of dollars and cents—this one's a strategic gambit aimed at...

Continue Reading

Top 5 Most Recently Viewed Articles

Synovus Appoints New Chattanooga Market Leader for Growth

Updated Category News Views 502

Synovus Appoints Jim Vaughn as Chattanooga Market Executive Synovus has recently made headlines by appointing Jim Vaughn as the new Chattanooga market executive. He brings a wealth of experience and has a solid background in the financial sector, joining from Mauldin & Jenkins, where he honed his skills over a significant tenure. Leadership Role and Responsibilities In...

Continue Reading
Navigating Recruitment Trends in Maritime and Oil & Gas for 2025

Updated Category News Views 85

Trends Shaping Recruitment in the Maritime and Oil & Gas Industries Core Group Resources stands at the forefront of talent acquisition, guiding businesses toward sustainable growth by effectively identifying and nurturing the right talent. As we approach 2025, the company has unveiled a comprehensive analysis detailing the pivotal trends that will influence recruitment...

Continue Reading
Disney and Netflix Stocks Dip Amid Warner Bros. Merger News

Updated Category News Views 430

Disney and Netflix Stocks Experience a Decline Securities of Walt Disney Co (NYSE: DIS) and Netflix Inc (NASDAQ: NFLX) are witnessing a downward trend, likely influenced by recent reports concerning a significant business maneuver involving Warner Bros. Discovery Inc (NASDAQ: WBD). Speculation arises that a coalition led by Paramount Skydance Corp (NASDAQ: PSKY) is...

Continue Reading
Alpine Income Property Trust Launches New Preferred Stock Offering

Updated Category News Views 136

Alpine Income Property Trust Announces Public Offering Alpine Income Property Trust, Inc. (NYSE: PINE) has officially announced the launch of its public offering for the Series A Cumulative Redeemable Preferred Stock, which has a liquidation preference of $25.00 per share. This initiative reflects the company’s strategic approach to expanding its capital base and...

Continue Reading
Civitas Capital Strengthens Team with New Regional Director

Updated Category News Views 127

Civitas Capital Welcomes Rishabh Gandhi Civitas Capital is thrilled to announce a significant addition to our team: Rishabh Gandhi, who joins us as Regional Director for India and the Middle East. With over nine years of invaluable experience in the EB-5 investment industry, Rishabh brings a wealth of expertise, strategic insight, and an established network of...

Continue Reading